[Antiemetic efficacy of high-dose metoclopramide, diphenhydramine, methylprednisolone and diazepam on chemotherapy-induced emesis in gynecological malignancy].
The antiemetic efficacy of high-dose metoclopramide (MCP), diphenhydramine (DPH), methylprednisolone (MPL), and diazepam (DZP) was investigated in 40 gynecologic cancer patients for a total of 98 chemotherapy courses, treated with cisplatin (50 mg/m2). With MPL (500 mg i.v. x 2) plus DZP (5 mg i.m. x 2), no vomiting occurred in 0% and mild emesis (vomiting 1-2 times) occurred in 20% of 25 courses. With MCP (2 mg/kg i.v. x 5) plus DPH (40 mg i.v. x 3), no vomiting occurred in 35% and mild emesis occurred in 10% of 20 courses. With a combination of MCP plus DPH and MPL plus DZP, no vomiting occurred in 51% and mild emesis occurred in 25% of 53 courses. These results indicate that high-dose MCP plus DPH are effective in preventing cisplatin-induced vomiting. Furthermore, the antiemetic efficacy of MCP plus DPH (0-2 vomiting episodes: 45%) was significantly enhanced (p less than 0.05) by the combined use of MPL plus DZP (0-2 vomiting episodes: 76%).
Department of Obstetrics and Gynecology, Saga Medical School.
Y
Y
Hayashi
T
T
Iwasaka
T
T
Hachisuga
K
K
Fukuda
T
T
Tanaka
N
N
Matsuo
H
H
Sugimori
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects*; D003975:Diazepam / Q000008:administration & dosage*; D004155:Diphenhydramine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage*; D008787:Metoclopramide / Q000008:administration & dosage*; D008875:Middle Aged; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D004155:Diphenhydramine; D008787:Metoclopramide; D002945:Cisplatin; D003975:Diazepam; D008775:Methylprednisolone